Business
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), the global l...
About this update from Medx Health Corp.
[{"type":"text","content":"MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of\n \n Meghan Geary\n \n as the Company’s\n \n Senior Vice President of Operations\n \n , effective immediately.\n \n\n With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory.\n \n\n \"I'm excited to join MedX at such a pivotal stage of its journey,\" said Geary. \"Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success.\"\n \n\n The Company’s CEO, John Gevisser added: “Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.”\n \n\n\n About MedX Health Corp.\n \n\n\n MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy\n \n ®\n \n technology, integrated into the DermSecure\n \n ®\n \n platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration (‘FDA’), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, les...